Clinical Trial Update: A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China [Phase 1]

View source ↗

Summary

Phase I clinical study of JS004 in subjects with recurrent or refractory malignant lymphoma in China has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Lymphoma

Drugs mentioned

• JS004 (JS004)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Recurrent/Refractory Malignant Lymphoma | Phase 1 | Status: COMPLETED